SafeChemo is an EU-funded project coordinated by B.Braun Melsungen AG, which brings together prestigious European healthcare institutions and leading edge industry players. The project targets the validation of Health Robotics' CytoCare™ system, a tool to increase patient safety, lower operators’ risk and reduce operating costs in the critical area of cancer care.
SafeChemo aims at coupling technology implementation with a clinical reengineering approach. The three European pilot sites - the Imperial College Healthcare NHS Trust of London (UK), the Capital Region Pharmacy of Copenhagen (DK), and the South Tyrol Healthcare Trust of Bolzano (I) - have developed a joint validation protocol and defined outcome measures for efficiency, safety and human factors. The final results of the project will be published as a scientific paper in the second half of 2009.
If you want to find out more about the preliminary results, please read the articles or download the poster on operator exposure published at the 2008 EAHP meeting in Barcelona.